AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10608746 — intervention group
Group type: EXPERIMENTAL
Intervention: pleconaril 200 mg twice daily (initial dose of 400 mg)
Number of subjects: 33
Study 10608746 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 33
Study 8859234 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mg intravenous ondansetron
Number of subjects: 32
Study 8859234 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 32
Study 7959523 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (1x20 mg/day)
Number of subjects: 60
Study 7959523 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin (2x50 mg/day)
Number of subjects: 60
Study 7959523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 3298420 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (selective MAO-A-inhibitor)
Number of subjects: 23
Study 30153034 — intervention group
Group type: EXPERIMENTAL
Intervention: Highlighted utensils
Number of subjects: 0
Study 30153034 — intervention group
Group type: COMPARATOR
Intervention: Non-highlighted utensils
Number of subjects: 0
Study 30153034 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark setting
Number of subjects: 0
Study 30153034 — intervention group
Group type: COMPARATOR
Intervention: Normal vision setting
Number of subjects: 0
Study 26109687 — intervention group
Group type: EXPERIMENTAL
Intervention: Kyphoplasty
Number of subjects: 115
Study 26109687 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 115
Study 26109687 — intervention group
Group type: COMPARATOR
Intervention: Kyphoplasty vs Vertebroplasty
Number of subjects: 115
Study 25301859 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with severe aortic valve stenosis
Number of subjects: 1611
Study 25301859 — intervention group
Group type: COMPARATOR
Intervention: Men with severe aortic valve stenosis
Number of subjects: 1611
Study 25301859 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 1611
Study 25301859 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 1611
Study 24082728 — intervention group
Group type: EXPERIMENTAL
Intervention: OHA + 50 mg elemental zinc as zinc sulphate supplementation for 12 weeks
Number of subjects: 54
Study 24082728 — intervention group
Group type: COMPARATOR
Intervention: OHA alone
Number of subjects: 54
Study 21148439 — intervention group
Group type: EXPERIMENTAL
Intervention: Very early and intensive mobilization group
Number of subjects: 71
Study 21148439 — intervention group
Group type: COMPARATOR
Intervention: Standard stroke unit care (Control)
Number of subjects: 71
Study 18816492 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg aspirin daily
Number of subjects: 37
Study 18816492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 17164695 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose activated charcoal (SDAC)
Number of subjects: 0
Study 17164695 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose activated charcoal (MDAC)
Number of subjects: 0
Study 17164695 — intervention group
Group type: COMPARATOR
Intervention: No activated charcoal (NoAC)
Number of subjects: 0
Study 12959631 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 51
Study 12959631 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or standard treatment)
Number of subjects: 51
Study 10922195 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia (2% lidocaine, minimum of 5 doses, approximately 40 microL per dose)
Number of subjects: 476
Study 10922195 — intervention group
Group type: COMPARATOR
Intervention: Retrobulbar anesthesia (3.5-5.5 mL of a combination of 0.75% bupivacaine hydrochloride, 2% lidocaine, and hyaluronidase)
Number of subjects: 476
Study 10922195 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia
Number of subjects: 476
Study 10922195 — intervention group
Group type: COMPARATOR
Intervention: Retrobulbar anesthesia
Number of subjects: 476
Study 8786727 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg subcutaneously)
Number of subjects: 18
Study 8786727 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (1 microgram/kg body weight intravenous bolus)
Number of subjects: 18
Study 8786727 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (50 g in 50 mL normal saline over 30 minutes)
Number of subjects: 18
Study 8786727 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 18
Study 2199394 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchiectomy
Number of subjects: 78
Study 2199394 — intervention group
Group type: COMPARATOR
Intervention: High dose polyoestradiol phosphate (160 mg i.m. monthly)
Number of subjects: 78
Study 686549 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise for 1 hour three times a week
Number of subjects: 18
Study 686549 — intervention group
Group type: COMPARATOR
Intervention: Sedentary group (Control)
Number of subjects: 18
Study 686549 — intervention group
Group type: COMPARATOR
Intervention: Exercise vs Sedentary
Number of subjects: 18
Study 30931665 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (90 seconds)
Number of subjects: 128
Study 30931665 — intervention group
Group type: COMPARATOR
Intervention: Early cord clamping (<30 seconds)
Number of subjects: 128
Study 30931665 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 128
Study 30929591 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise treatment group (n = 21)
Number of subjects: 40
Study 30929591 — intervention group
Group type: COMPARATOR
Intervention: No-aerobic control group (n = 19)
Number of subjects: 40
Study 28937828 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin hydrochloride (AH)
Number of subjects: 63
Study 28937828 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin hydrochloride (TH)
Number of subjects: 63
Study 24642450 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy food frequency questionnaire
Number of subjects: 54
Study 24642450 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline isoflavone concentrations (genistein and daidzein)
Number of subjects: 54
Study 24642450 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine concentrations of isoflavones
Number of subjects: 54
Study 24642450 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly estimated intake of isoflavones
Number of subjects: 54
Study 24642450 — intervention group
Group type: EXPERIMENTAL
Intervention: Spearman's rank correlation coefficient
Number of subjects: 54
Study 23079866 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable resistance (15 × 1 repetition maximum)
Number of subjects: 25
Study 23079866 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable resistance (5 × 10 repetitions)
Number of subjects: 25
Study 23079866 — intervention group
Group type: EXPERIMENTAL
Intervention: All loading protocols
Number of subjects: 25
Study 23079866 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable resistance loadings
Number of subjects: 25
Study 21605003 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat exposure without vascular occlusion at temperatures of 32, 36, 38, or 40 °C for 6 minutes
Number of subjects: 20
Study 19520448 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 Gy single-dose RT
Number of subjects: 327
Study 19520448 — intervention group
Group type: COMPARATOR
Intervention: 8 Gy x 2 RT
Number of subjects: 327
Study 19520448 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RT schedules
Number of subjects: 327
Study 16616994 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (HYD) doses of 12 mg and 24 mg IM
Number of subjects: 13
Study 16616994 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-session supplements of HYD (12 mg or 24 mg)
Number of subjects: 13
Study 16616994 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine use prior to the experiment
Number of subjects: 13
Study 16616994 — intervention group
Group type: EXPERIMENTAL
Intervention: Different FR/unit dose combinations
Number of subjects: 13
Study 14872155 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0
Study 11323364 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg epidural S(+)‐ketamine
Number of subjects: 37
Study 11323364 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine (10 mg/mL, 10‐20 mL)
Number of subjects: 37
Study 11323364 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine and ropivacaine
Number of subjects: 37
Study 9150295 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 48
Study 9150295 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 48
Study 8001898 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous monophasic shock waveforms with bidirectional lead configuration
Number of subjects: 86
Study 8001898 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous monophasic and biphasic waveforms with a fixed pulse duration of 6.3 ms
Number of subjects: 86
Study 8001898 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous monophasic and biphasic shocks with a constant tilt using undirectional lead configuration
Number of subjects: 86
Study 8001898 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic and triphasic shock waveforms with a fixed pulse duration of 10 ms
Number of subjects: 86
Study 3196888 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen
Number of subjects: 23
Study 3196888 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 23
Study 31884870 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback device
Number of subjects: 203
Study 31884870 — intervention group
Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 203
Study 31722259 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyad training with physical and observational practice and inter‐trial dialogue
Number of subjects: 40
Study 31722259 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyad training with physical practice and dialogue without observation
Number of subjects: 40
Study 31722259 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyad training with physical and observational practice without dialogue
Number of subjects: 40
Study 31722259 — intervention group
Group type: COMPARATOR
Intervention: Individual practice control group
Number of subjects: 40
Study 28343225 — intervention group
Group type: EXPERIMENTAL
Intervention: Vadadustat (240, 370, 500, or 630 mg once-daily for 6 weeks)
Number of subjects: 93
Study 28343225 — intervention group
Group type: EXPERIMENTAL
Intervention: Vadadustat
Number of subjects: 93
Study 26304864 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferoxamine infusion
Number of subjects: 48
Study 23545931 — intervention group
Group type: EXPERIMENTAL
Intervention: SkinMedica® Hyperpigmentation System (HQ-free)
Number of subjects: 36
Study 23545931 — intervention group
Group type: COMPARATOR
Intervention: Obagi Nu‐Derm System (HQ-based)
Number of subjects: 36
Study 21171737 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented self-help
Number of subjects: 262
Study 21171737 — intervention group
Group type: COMPARATOR
Intervention: Standard self-help
Number of subjects: 262
Study 21171737 — intervention group
Group type: COMPARATOR
Intervention: No-intervention
Number of subjects: 262
Study 19066101 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally-invasive surgery plus rtPA
Number of subjects: 100
Study 19066101 — intervention group
Group type: COMPARATOR
Intervention: Standard medical management
Number of subjects: 100
Study 16880092 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal septal myocardial ablation
Number of subjects: 16
Study 16880092 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (12 healthy individuals)
Number of subjects: 16
Study 12915013 — intervention group
Group type: EXPERIMENTAL
Intervention: Kit delivery and counseling (group 1)
Number of subjects: 100
Study 12915013 — intervention group
Group type: COMPARATOR
Intervention: Counseling without the kit (group 2)
Number of subjects: 100
Study 10743877 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming of a stress word
Number of subjects: 0
Study 10743877 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive load conditions
Number of subjects: 0
Study 8706772 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered sublingual captopril (12.5 mg)
Number of subjects: 6
Study 8706772 — intervention group
Group type: COMPARATOR
Intervention: Peroral captopril (administered with 100 ml of water)
Number of subjects: 6
Study 1395644 — intervention group
Group type: EXPERIMENTAL
Intervention: Right brain-damaged patients (RBD)
Number of subjects: 39
Study 1395644 — intervention group
Group type: COMPARATOR
Intervention: Left brain-damaged patients (LBD)
Number of subjects: 39
Study 1395644 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked presentations
Number of subjects: 39
Study 1395644 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral stimulus presentation
Number of subjects: 39
Study 6143667 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg b.i.d.
Number of subjects: 13
Study 6143667 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg b.i.d.
Number of subjects: 13
Study 6143667 — intervention group
Group type: COMPARATOR
Intervention: Placebo b.i.d.
Number of subjects: 13
Study 30561711 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational arms
Number of subjects: 51
Study 30561711 — intervention group
Group type: COMPARATOR
Intervention: Control arms
Number of subjects: 51
Study 30561711 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind trials
Number of subjects: 51
Study 30561711 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label trials
Number of subjects: 51
Study 29217088 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction cisplatin (80 mg/m2) and docetaxel (75 mg/m2) for 3 cycles followed by surgery and adjuvant erlotinib for 12 months
Number of subjects: 47
Study 29217088 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction cisplatin and docetaxel
Number of subjects: 47
Study 29217088 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant erlotinib
Number of subjects: 47
Study 29217088 — intervention group
Group type: EXPERIMENTAL
Intervention: Major pathologic response
Number of subjects: 47
Study 29217088 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete pathologic response in mediastinal/hilar nodes
Number of subjects: 47
Study 26763489 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine 2.5 mg BID
Number of subjects: 126
Study 26763489 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine 5 mg BID
Number of subjects: 126
Study 26763489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 25041182 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic doxycycline for 21 days
Number of subjects: 66
Study 25041182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 21153418 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of venous outflow from the exercised leg for 18 minutes by inflating a cuff around the thigh immediately following exercise.
Number of subjects: 6
Study 21153418 — intervention group
Group type: COMPARATOR
Intervention: Control occasion with no inhibition of venous outflow.
Number of subjects: 6
Study 19245075 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG stimulation
Number of subjects: 29
Study 19245075 — intervention group
Group type: COMPARATOR
Intervention: Basal inhibin B levels
Number of subjects: 29
Study 17086855 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splint (treated group)
Number of subjects: 84
Study 17086855 — intervention group
Group type: COMPARATOR
Intervention: No splint (control group)
Number of subjects: 84
Study 15205987 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg diclofenac daily
Number of subjects: 245
Study 15205987 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg diclofenac daily
Number of subjects: 245
Study 15205987 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 245
Study 11449205 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 400 microg once daily
Number of subjects: 0
Study 11449205 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (BUD) 200 microg once daily
Number of subjects: 0
Study 11449205 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate (MF) 100 microg once daily
Number of subjects: 0
Study 11449205 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate (MF) 200 microg once daily
Number of subjects: 0
Study 11449205 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 84 microg twice daily
Number of subjects: 0
Study 11449205 — intervention group
Group type: COMPARATOR
Intervention: Inhaled beclomethasone dipropionate or BUD
Number of subjects: 0
Study 9412707 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved case management for sexually transmitted diseases (STD) using the syndromic approach in rural health units.
Number of subjects: 12534
Study 9412707 — intervention group
Group type: COMPARATOR
Intervention: Comparison community (no improved case management).
Number of subjects: 12534
Study 9412707 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved case management for STD.
Number of subjects: 12534
Study 7522528 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 0
Study 7522528 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic‐intestinal and multivisceral transplantation
Number of subjects: 0
Study 2890805 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi capsular polysaccharide (CPS) vaccine (25 micrograms, single intramuscular injection)
Number of subjects: 11384
Study 876669 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg morphine
Number of subjects: 24
Study 876669 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg codeine
Number of subjects: 24
Study 876669 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg aspirin
Number of subjects: 24
Study 876669 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 30575287 — intervention group
Group type: EXPERIMENTAL
Intervention: Pupil expansion device
Number of subjects: 536
Study 30575287 — intervention group
Group type: COMPARATOR
Intervention: No pupil expansion device
Number of subjects: 536
Study 27885163 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm Motor Ability Test (AMAT) intervention
Number of subjects: 146
Study 26347971 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 80
Study 26347971 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium
Number of subjects: 80
Study 23614336 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemetric body weight measurement (TBWM)
Number of subjects: 120
Study 23614336 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment without telemetric monitoring (Control Group)
Number of subjects: 120
Study 22390033 — intervention group
Group type: EXPERIMENTAL
Intervention: Opening-window on thermoplastic mask (test group)
Number of subjects: 73
Study 22390033 — intervention group
Group type: COMPARATOR
Intervention: Intact thermoplastic mask (control group)
Number of subjects: 73
Study 19537368 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 20
Study 19537368 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream (placebo)
Number of subjects: 20
Study 17413098 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose supplemented with branched-chain amino acids (isoleucine, leucine, valine)
Number of subjects: 12
Study 17413098 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose supplemented with leucine, isoleucine, valine, lysine, and threonine
Number of subjects: 12
Study 17413098 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein drink
Number of subjects: 12
Study 17413098 — intervention group
Group type: COMPARATOR
Intervention: Reference drink (pure glucose)
Number of subjects: 12
Study 15138417 — intervention group
Group type: COMPARATOR
Intervention: Multi‐Test II
Number of subjects: 40
Study 15138417 — intervention group
Group type: EXPERIMENTAL
Intervention: IDT
Number of subjects: 40
Study 11679990 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary portocaval shunt (PCS)
Number of subjects: 80
Study 11679990 — intervention group
Group type: COMPARATOR
Intervention: No temporary portocaval shunt (no-PCS)
Number of subjects: 80
Study 9080896 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-switched ruby laser (694 nm)
Number of subjects: 5
Study 9080896 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-switched neodymium: YAG laser (1064 nm)
Number of subjects: 5
Study 9080896 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 5
Study 8199752 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocloprost clathrate (400 micrograms)
Number of subjects: 15
Study 8199752 — intervention group
Group type: COMPARATOR
Intervention: Placebo (with and without equivalent amounts of beta-cyclodextrin)
Number of subjects: 15
Study 3330992 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (30-60 mg/day)
Number of subjects: 29
Study 3330992 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25-50 mg/day)
Number of subjects: 29
Study 3330992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 29381560 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (3-g pill daily for 12 weeks, containing 1.8-g eicosapentaenoic acid and 1.2-mg docosapentaenoic acid)
Number of subjects: 67
Study 29381560 — intervention group
Group type: COMPARATOR
Intervention: Placebo (44.8 mg of high oleic safflower oil)
Number of subjects: 67
Study 29381560 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (specific to Kaposi sarcoma patients)
Number of subjects: 67
Study 29381560 — intervention group
Group type: COMPARATOR
Intervention: Placebo (specific to Kaposi sarcoma patients)
Number of subjects: 67
Study 27317632 — intervention group
Group type: EXPERIMENTAL
Intervention: α1‐adrenergic blockade (oral Prazosin, 0.05 mg/kg)
Number of subjects: 18
Study 27317632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18